P&G Open To M&A Moves, Closed To Board Seat For Activist Investor
This article was originally published in The Pink Sheet
Executive Summary
P&G posts 2% organic growth in its latest quarter and its adjusted EPS beat analyst expectations as it is again interested in M&A. A few days after releasing its results, company appeals to shareholders to vote against an activist investor's bid for a board seat.
You may also be interested in...
Investor Critical Of P&G Management Before Election To Board Follows CEO Out The Door
In tones completely opposite from when Nelson Peltz sought a board seat in 2017, P&G CEO David Taylor and Peltz congratulated each other in P&G’s announcement.
Activist Investor Forces P&G's Hand: Shareholder Vote On Joining Board
Nelson Peltz's Trian Fund Management, with a stake of around 1.5%, isn't satisfied with P&G progress from multiple initiatives across more than five years toward gaining market share for its health, personal and household care products and increasing margins.
'Slow-Growth' Global Trend Shakes Up P&G Product Strategy Start To Finish
P&G’s health care segment advanced 4% in the third quarter to $1.84bn, but sales declined for its other business units, a trend the firm sees worldwide across consumer industries. CFO Jon Moeller unveils the firm’s “irresistible superiority” product development strategy to counter slower global consumer spending.